254 related articles for article (PubMed ID: 25878175)
21. Prevention of generalized tonic-clonic seizures in refractory focal epilepsy: a meta-analysis.
Hemery C; Ryvlin P; Rheims S
Epilepsia; 2014 Nov; 55(11):1789-99. PubMed ID: 25182978
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: A phase III post-hoc analysis.
Glauser T; Laurenza A; Yang H; Williams B; Ma T; Fain R
Epilepsy Res; 2016 Jan; 119():34-40. PubMed ID: 26656783
[TBL] [Abstract][Full Text] [Related]
23. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S
Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772
[TBL] [Abstract][Full Text] [Related]
24. Time to exceed pre-randomization monthly seizure count for perampanel in participants with primary generalized tonic-clonic seizures: A potential clinical end point.
Kerr WT; Brandt C; Ngo LY; Patten A; Cheng JY; Kramer L; French JA
Epilepsia; 2022 Nov; 63(11):2994-3004. PubMed ID: 36106379
[TBL] [Abstract][Full Text] [Related]
25. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.
French JA; Krauss GL; Wechsler RT; Wang XF; DiVentura B; Brandt C; Trinka E; O'Brien TJ; Laurenza A; Patten A; Bibbiani F
Neurology; 2015 Sep; 85(11):950-7. PubMed ID: 26296511
[TBL] [Abstract][Full Text] [Related]
26. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures.
Piña-Garza JE; Lagae L; Villanueva V; Renfroe JB; Laurenza A; Williams B; Kumar D; Meador KJ
Epilepsy Behav; 2018 Jun; 83():50-58. PubMed ID: 29653338
[TBL] [Abstract][Full Text] [Related]
27. Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: Analysis of four open-label extension studies.
Rektor I; Krauss GL; Inoue Y; Kaneko S; Williams B; Patten A; Malhotra M; Laurenza A; Wechsler RT
Epilepsia; 2020 Jul; 61(7):1491-1502. PubMed ID: 32645213
[TBL] [Abstract][Full Text] [Related]
28. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307.
Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Clément JF; Wang X; Bagul M; Gee M; Zhu J; Squillacote D
Epilepsia; 2014 Jul; 55(7):1058-68. PubMed ID: 24867391
[TBL] [Abstract][Full Text] [Related]
29. Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies.
Kramer LD; Satlin A; Krauss GL; French J; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Laurenza A; Yang H; Zhu J; Squillacote D
Epilepsia; 2014 Mar; 55(3):423-31. PubMed ID: 24605793
[TBL] [Abstract][Full Text] [Related]
30. Efficacy, safety, and tolerability of perampanel in Asian and non-Asian patients with epilepsy.
Tsai JJ; Ikeda A; Hong SB; Likasitwattanakul S; Dash A
Epilepsia; 2019 Mar; 60 Suppl 1():37-46. PubMed ID: 30869165
[TBL] [Abstract][Full Text] [Related]
31. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety.
Lagae L; Villanueva V; Meador KJ; Bagul M; Laurenza A; Kumar D; Yang H
Epilepsia; 2016 Jul; 57(7):1120-9. PubMed ID: 27221398
[TBL] [Abstract][Full Text] [Related]
32. Prospective audit with adjunctive perampanel: Preliminary observations in focal epilepsy.
Brodie MJ; Stephen LJ
Epilepsy Behav; 2016 Jan; 54():100-3. PubMed ID: 26700063
[TBL] [Abstract][Full Text] [Related]
33. Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings.
Tsai JJ; Wu T; Leung H; Desudchit T; Tiamkao S; Lim KS; Dash A
Acta Neurol Scand; 2018 Apr; 137(4):378-391. PubMed ID: 29214650
[TBL] [Abstract][Full Text] [Related]
34. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy.
Gidal BE; Laurenza A; Hussein Z; Yang H; Fain R; Edelstein J; Kumar D; Ferry J
Neurology; 2015 May; 84(19):1972-80. PubMed ID: 25878177
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV
Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147
[TBL] [Abstract][Full Text] [Related]
36. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
37. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes.
Kwan P; Brodie MJ; Laurenza A; FitzGibbon H; Gidal BE
Epilepsy Res; 2015 Nov; 117():117-24. PubMed ID: 26448264
[TBL] [Abstract][Full Text] [Related]
38. Analysis of falls in patients with epilepsy enrolled in the perampanel phase III randomized double-blind studies.
Leppik IE; Yang H; Williams B; Zhou S; Fain R; Patten A; Bibbiani F; Laurenza A
Epilepsia; 2017 Jan; 58(1):51-59. PubMed ID: 27869305
[TBL] [Abstract][Full Text] [Related]
39. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
[TBL] [Abstract][Full Text] [Related]
40. Sustained seizure freedom with adjunctive perampanel in patients with convulsive seizures: Post hoc analysis of open-label extension studies 307 and 332.
Resnick T; Patten A; Ngo LY; Malhotra M
Epilepsy Behav; 2022 Mar; 128():108528. PubMed ID: 35078116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
